FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3105587777> ?p ?o ?g. }

• W3105587777 endingPage "1926" @default.
• W3105587777 startingPage "1925" @default.
• W3105587777 abstract "Transoral robotic surgery (TORS) has become increasingly accepted as a treatment modality in Human papillomavirus (HPV) positive T1/T2 oropharyngeal squamous cell carcinoma (OPSCC). Various studies have shown better oncologic and survival outcomes in HPV positive OPSCC patients, compared to HPV negative OPSCC. National Comprehensive Cancer Network (NCCN) guidelines recommend surgical excision or radiotherapy in T1/T2 OPSCC for both HPV positive as well as HPV negative tumors.1 Results have been comparable when HPV positive OPSCC patients have been treated with TORS versus radiotherapy in early stage disease. However, the role of TORS in HPV negative OPSCC has not been well elucidated. Existing literature focuses on the surgical outcomes of HPV positive OPSCC especially with TORS; however, the results of surgical and oncologic outcomes in HPV negative OPSCC patients have been largely limited to subset analysis of large OPSCC cohorts. There are no large-scale prospective trials, which have studied TORS in HPV negative OPSCC. In fact, a Phase II randomized controlled trial (RTOG 1221, NCT01953952) was formulated to compare the survival outcomes in patients with T1/T2, N1-N2b HPV negative OPSCC, but unfortunately this trial was closed due to poor accrual rate and a relative decline in HPV-negative OPSCC. This review summarizes the available literature and investigates the role of TORS in HPV negative OPSCC. Baliga et al. recently published the outcomes of a large cohort of 17,150 T1/T2 OPSCC patients, 2680 of which underwent TORS from a National cancer database (NCDB) query.2 The authors reported that the differences in overall survival (OS) between HPV positive and HPV negative groups were not statistically significant. (HPV positive: Hazard ratio HR 0.75, P = .20 and HPV negative HR 0.84, P = .43). The authors commented that the role of TORS in HPV negative OPSCC has not been well documented as there is a dearth of prospective studies looking at this cohort of patients. Another study by Mahmoud et al. queried the NCDB for outcomes of TORS in OPSCC.3 One hundred eight patients were HPV negative. On a subset analysis using the proportional hazards model, 103 HPV negative patients who underwent TORS were compared with 103 case-matched HPV negative patients with radiotherapy. The 3-year survival was 84% {(95% confidence interval CI 76%–91%) versus 66% (95% CI 57%–77%) P = .01} for TORS versus radiotherapy, respectively. These results suggest that surgery for HPV negative OPSCC is feasible with reasonable oncologic outcomes. The authors commented that until prospective studies are designed to investigate the outcomes of surgery in HPV negative OPSCC, large datasets like the NCDB should be explored to answer this question. These studies correlated well with the promising results of a multi-institutional retrospective study by de Almeida in 2015.4 A subset analysis of 61 HPV negative OPSCC patients who underwent TORS was performed. The authors did not report any statistically significant differences in survival between the HPV positive and HPV negative groups. The 2-year locoregional control rate was 95% and 92% (P = .52) among HPV positive and HPV negative patients, respectively. Further, the 2 years OS was 96.7% and 93.7% (P = .23) among HPV positive and HPV negative patients, respectively. The authors, however, felt that their finding of OPSCC patients having comparable survival following TORS, irrespective of the HPV status needed further validation as the number of HPV negative patients was low in their study. Results from a recent prospective trial published by Dabas et al. aimed to investigate the long-term oncologic outcomes in HPV negative node negative OPSCC.5 Results were analyzed for 49 patients. All patients underwent a neck dissection and as they were pathologically staged as Stage I/II, none received any adjuvant therapy. The mean follow-up period was for 29 months (range: 15–47 months). The disease-free survival (DFS) and OS were 89.6% and 93.8%, respectively. These rates were similar to the ones observed in various retrospective and population registry studies (Table I).2-4 However, while prospectively collected, these results should be interpreted with caution, as this study was not randomized and contained no comparison or control group. The possible need for chemotherapy and radiation following surgery remains a contentious issue. Some practitioners would argue against TORS for HPV-negative disease given the high risk of subjecting the patient to tri-modality therapy if there are post-operative concerns such as positive margins or extracapsular nodal extension. However, others would argue that the relatively poor locoregional control rates and survival with HPV negative disease warrants exploration of treatment intensification modalities. Surgical margin status is also a controversial issue in TORS especially in HPV negative patients. It is difficult to achieve comparable margins to open surgery. In de Almeida et al, 9.9% of patients had positive margins and 21.0% had close margins of 1 mm to 5 mm, with a number of patients having unspecified margin status (37.6%).4 The data on outcomes following TORS for HPV negative OPSCC is limited. However, subset analysis from larger retrospective and database studies on early stage HPV positive OPSCC suggests acceptable survival and oncologic outcomes. Thus, based on the available data, upfront TORS in selected HPV negative patients may be an option in the treatment algorithm with radiotherapy being reserved for tumors, which are not amenable to TORS, and in adjuvant settings. Further studies are required to determine optimum margins in TORS for such patients. Recognizing the technical difficulties of doing so, standard margins of 5 mm should be achieved until further data is available. The decision to offer TORS to HPV negative patients should be made by factoring in multidisciplinary expertise, patient preference, and an awareness of the limitations of the current available evidence. Reference 1,2,3,4 – level 4; Reference 5, − level 3" @default.
• W3105587777 created "2020-11-23" @default.
• W3105587777 creator A5003318723 @default.
• W3105587777 creator A5075960901 @default.
• W3105587777 creator A5076122892 @default.
• W3105587777 date "2020-11-10" @default.
• W3105587777 modified "2023-10-17" @default.
• W3105587777 title "What is the Role of Trans‐Oral Robotic Surgery (<scp>TORS</scp>) in <scp>HPV</scp> Negative Oropharyngeal Cancer?" @default.
• W3105587777 cites W2149366965 @default.
• W3105587777 cites W2606848625 @default.
• W3105587777 cites W2774655557 @default.
• W3105587777 cites W2891963548 @default.
• W3105587777 doi "https://doi.org/10.1002/lary.29251" @default.
• W3105587777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33169856" @default.
• W3105587777 hasPublicationYear "2020" @default.
• W3105587777 type Work @default.
• W3105587777 sameAs 3105587777 @default.
• W3105587777 citedByCount "0" @default.
• W3105587777 crossrefType "journal-article" @default.
• W3105587777 hasAuthorship W3105587777A5003318723 @default.
• W3105587777 hasAuthorship W3105587777A5075960901 @default.
• W3105587777 hasAuthorship W3105587777A5076122892 @default.
• W3105587777 hasBestOaLocation W31055877771 @default.
• W3105587777 hasConcept C121608353 @default.
• W3105587777 hasConcept C126322002 @default.
• W3105587777 hasConcept C141071460 @default.
• W3105587777 hasConcept C143998085 @default.
• W3105587777 hasConcept C168563851 @default.
• W3105587777 hasConcept C2908642260 @default.
• W3105587777 hasConcept C2994532551 @default.
• W3105587777 hasConcept C509974204 @default.
• W3105587777 hasConcept C71924100 @default.
• W3105587777 hasConcept C72563966 @default.
• W3105587777 hasConceptScore W3105587777C121608353 @default.
• W3105587777 hasConceptScore W3105587777C126322002 @default.
• W3105587777 hasConceptScore W3105587777C141071460 @default.
• W3105587777 hasConceptScore W3105587777C143998085 @default.
• W3105587777 hasConceptScore W3105587777C168563851 @default.
• W3105587777 hasConceptScore W3105587777C2908642260 @default.
• W3105587777 hasConceptScore W3105587777C2994532551 @default.
• W3105587777 hasConceptScore W3105587777C509974204 @default.
• W3105587777 hasConceptScore W3105587777C71924100 @default.
• W3105587777 hasConceptScore W3105587777C72563966 @default.
• W3105587777 hasIssue "9" @default.
• W3105587777 hasLocation W31055877771 @default.
• W3105587777 hasOpenAccess W3105587777 @default.
• W3105587777 hasPrimaryLocation W31055877771 @default.
• W3105587777 hasRelatedWork W2315085516 @default.
• W3105587777 hasRelatedWork W2316407790 @default.
• W3105587777 hasRelatedWork W2384708512 @default.
• W3105587777 hasRelatedWork W2395331253 @default.
• W3105587777 hasRelatedWork W2603773853 @default.
• W3105587777 hasRelatedWork W2964295425 @default.
• W3105587777 hasRelatedWork W3159250744 @default.
• W3105587777 hasRelatedWork W4256514411 @default.
• W3105587777 hasRelatedWork W4292236216 @default.
• W3105587777 hasRelatedWork W2083697902 @default.
• W3105587777 hasVolume "131" @default.
• W3105587777 isParatext "false" @default.
• W3105587777 isRetracted "false" @default.
• W3105587777 magId "3105587777" @default.
• W3105587777 workType "article" @default.